Christopher M. Nelson - 06 Feb 2024 Form 4 Insider Report for QSAM Biosciences, Inc.

Role
EVP Corp Dev & General Counsel
Signature
/s/ Christopher Nelson
Issuer symbol
N/A
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
13 Feb 2024, 16:00:23 UTC
Previous filing
23 Jun 2023
Next filing
02 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QSAM Common Stock Conversion of derivative security $26,049 +8,683 +5% $3.00 182,000 06 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QSAM Series B Convertible Preferred Stock Conversion of derivative security $26,049 0 06 Feb 2024 Common Stock 8,683 $3.00 Direct F1
holding QSAM Options to buy common stock 12,500 06 Feb 2024 Common Stock 12,500 $10.00 Direct F2
holding QSAM Options to buy common stock 2,875 06 Feb 2024 Common Stock 2,875 $14.40 Direct F3
holding QSAM Options to buy common stock 60 06 Feb 2024 Common Stock 60 $20.00 Direct
holding QSAM Options to buy common stock 255 06 Feb 2024 Common Stock 255 $20.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series B Convertible Preferred Stock was convertible into common stock at any time and had no expiration date. Pursuant to an Exchange Agreement signed by and between the Company and all Series B Preferred Stockholders as of 11/18/23, the Series B Preferred Stock was automatically exchangeable for common stock of the Issuer at a price of $3.00 per share upon the Issuer listing on Nasdaq or signing an agreement to be acquired.
F2 The option vests annually in two equal installments beginning on 3/3/2023.
F3 The option vested semi-annually in two equal installments beginning on 2/24/2022.